Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. on November 13, 2013. The filing discloses the entry into a material definitive agreement regarding a public offering of common stock. Note: The request metadata referenced "Madrigal Pharmaceuticals," but the source text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of common stock.
- Shares Offered: 14,000,000 shares at a public offering price of $3.75 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 2,100,000 shares.
- Expected Gross Proceeds: Approximately $52.5 million (excluding underwriting discounts, commissions, and expenses, and assuming no exercise of the over-allotment option).
- Expected Closing Date: On or about November 18, 2013.
- Underwriter: Jefferies LLC (as representative).
Material Changes and Director Participation
The filing details significant participation by company directors in the offering, with an aggregate of 5,183,333 shares allocated to them on the same terms as the public offering:
- Bruce Kovner: Purchasing 5,000,000 shares. Post-offering beneficial ownership is expected to be approximately 34.5% (up from 34.2%).
- Wyandanch Partners, L.P. (controlled by Director Keith R. Gollust): Purchasing 150,000 shares. Post-offering beneficial ownership is expected to be approximately 4.2% (down from 4.8% due to dilution).
- William S. Reardon: Purchasing 13,333 shares. Post-offering beneficial ownership remains less than 1%.
- Safi R. Bahcall, Ph.D. (CEO): Purchasing 20,000 shares. Post-offering beneficial ownership is expected to be approximately 3.7% (down from 4.4% due to dilution).
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding operational performance. The document focuses solely on the mechanics of the capital raise. Standard risk disclosures note that the offering is subject to customary closing conditions and that representations in the underwriting agreement are for the benefit of the contracting parties and should not be relied upon as characterizations of the company's actual state of facts by third-party investors.
Key Facts for Investor Verification
- Verify the final closing date and whether the underwriters exercised the 2,100,000 share over-allotment option.
- Confirm the net proceeds to the company after deducting underwriting discounts and offering expenses.
- Review the company's most recent 10-K or 10-Q to understand the intended use of the $52.5 million in gross proceeds (e.g., clinical trials, working capital).
- Monitor the post-offering share count to calculate the exact dilution impact on existing shareholders.